Core Insights - Devonian Health Group Inc. has filed a proprietary Thykamine™ fingerprint in recent patent applications, which is a key element of its long-term intellectual property strategy [1] - The Thykamine™ fingerprint identifies eight specific chemical components in precise ratios, validated through advanced HPLC-MS methods, showing 98% confidence in batch consistency [1] - The company emphasizes the quality and consistency of Thykamine™, which has demonstrated anti-inflammatory and anti-fibrotic properties in various studies, including a Phase IIa clinical study [1] Patent Strategy - The Thykamine™ fingerprint will be systematically included in all future patent filings related to Thykamine™ [1] - This strategy aims to strengthen the company's intellectual property portfolio and regulatory preparedness for pharmaceutical development [1] Manufacturing and Quality Control - HPLC-MS methodology has shown high reproducibility across manufactured batches, confirmed by NMR analysis [1] - Potency assays using a U-937 human cell-based model validated that each batch of Thykamine™ exhibits equivalent biological activity, consistently inhibiting key inflammatory cytokines [1] Product Overview - Thykamine™, developed from Devonian's SUPREX™ platform, targets health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [1] - The product's anti-inflammatory, anti-oxidative, and immunomodulatory properties have been supported by numerous in vitro and in vivo studies [1] Company Background - Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases [1] - The company also develops high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [1]

Core Insights - Devonian Health Group Inc. announced additional preclinical results from its STAM mouse model study, highlighting the anti-MASH, anti-inflammatory, and anti-fibrotic effects of Thykamine™ in liver conditions [1] Group 1: Study Results - The STAM mouse model study showed that Thykamine™ significantly reduced liver disease progression, inflammation, and fibrosis at doses of 0.5 mg/kg, 5.0 mg/kg, and 50.0 mg/kg over three weeks [1] - Gene expression analysis indicated a marked down-regulation of multiple genes central to MASH pathophysiology, with reductions approaching or exceeding 80-90% compared to placebo [1] - Thykamine™ treatment significantly modulated fibrosis-related genes such as CCN1, CCN2, COL1A1, and inflammation-related genes including CCL2 and IFNG, demonstrating a dose-dependent response [1] Group 2: Market Potential - The global MASH treatment market was valued at $7.87 billion in 2024 and is projected to reach $31.76 billion by 2033, growing at a 17.7% CAGR from 2025 to 2033 [1] - Nonalcoholic fatty liver disease (NAFLD), which progresses to MASH, has a worldwide prevalence of 20-30%, indicating a significant market opportunity for treatments targeting this condition [1] Group 3: Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory conditions, leveraging over 15 years of research [2] - The company is also involved in developing high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceutical products in Canada [2] - Devonian is publicly traded on the TSX Venture Exchange (TSXV: GSD) and OTCQB (OTCQB: DVHGF) [2]

Core Insights - Devonian Health Group Inc. reported positive results from a study on Thykamine™, demonstrating its potential as an antifibrotic treatment for pulmonary fibrosis, particularly in comparison to Pirfenidone [1][2] Company Overview - Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory conditions, leveraging over 15 years of research [2] - The company is headquartered in Québec, Canada, and is publicly traded on the TSX Venture Exchange (TSXV: GSD) and OTCQB (OTCQB: DVHGF) [2] Study Findings - The study utilized a bleomycin-induced pulmonary fibrosis mouse model, showing that Thykamine™ at a dose of 0.5 mg/kg significantly reduced lung wet weight and tissue index compared to the control group [1] - Thykamine™ treatment resulted in a statistically significant reduction in fibrosis and inflammation scores, indicating an improvement in lung morphology [1] - Key fibrosis- and inflammation-associated genes were downregulated with Thykamine™ treatment, suggesting controlled matrix remodeling and reduced fibrotic progression [1] Market Context - Pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), is a chronic and progressive disease with a poor prognosis, highlighting the urgent need for effective therapies [1] - The incidence and prevalence of IPF are increasing globally, driven by aging populations and improved diagnostic awareness, creating a significant unmet medical need [1] Product Information - Thykamine™, developed from Devonian's SUPREX™ platform, is positioned as a next-generation therapeutic candidate with potential applications in various fibroinflammatory diseases [1] - The product has demonstrated anti-inflammatory, anti-oxidative, and immunomodulatory properties in multiple studies, including a Phase IIa clinical study for ulcerative colitis and a Phase II study for atopic dermatitis [1][2]

Core Viewpoint - Devonian Health Group Inc. has announced the grant of stock options to its directors, employees, and consultants as part of its compensation strategy, reflecting the company's ongoing commitment to incentivize key personnel in the biopharmaceutical sector focused on inflammatory diseases [1][2][3]. Stock Options Grant - The Board of Directors approved the granting of a total of 2,948,056 stock options, with 2,798,056 options allocated to directors at an exercise price of $0.18, valid for 10 years [2]. - Additionally, 385,950 stock options were granted to employees as performance bonuses, with a vesting schedule of 25% on the grant date and 25% per year for the next three years [3]. Product Development - Devonian's flagship product, Thykamine™, is designed for the prevention and treatment of inflammatory and oxidative stress-related health conditions, including ulcerative colitis and atopic dermatitis, supported by extensive clinical studies [4]. - The company operates under the SUPREX™ platform, which is patented in multiple regions, enhancing its competitive edge in the biopharmaceutical market [4]. Company Overview - Devonian Health Group Inc. is a clinical-stage pharmaceutical company established in 2015, focusing on innovative treatments for autoimmune inflammatory conditions [5][7]. - The company also develops high-value cosmeceutical products and has a subsidiary, Altius, dedicated to selling prescription pharmaceuticals in Canada [6].

Core Insights - Devonian Health Group Inc. has published a peer-reviewed article in Biomedicines highlighting the anti-inflammatory properties of its lead pharmaceutical candidate, Thykamine™ [1][2] - The study demonstrates that Thykamine™ exhibits greater potency in inhibiting inflammatory markers compared to six widely prescribed anti-inflammatory drugs [3][4] - Thykamine™ is positioned as a promising candidate for treating chronic inflammatory conditions due to its favorable safety profile and multi-target efficacy [4][6] Company Overview - Devonian Health Group Inc. specializes in developing prescription drugs for fibroinflammatory diseases and has a focus on unmet medical needs in autoimmune inflammatory conditions [10] - The company’s first pharmaceutical product, Thykamine™, is derived from its SUPREX™ platform and has shown efficacy in treating conditions like ulcerative colitis and atopic dermatitis [8][10] - Devonian is publicly traded on the TSX Venture Exchange and OTCQB Venture Market, and it operates a state-of-the-art extraction facility in Québec, Canada [12]

Core Viewpoint - Devonian Health Group Inc. reported its financial results for the fourth quarter and fiscal year ended July 31, 2025, highlighting a debt-free status and a strategic focus on advancing its Thykamine™ programs in the fibro-inflammatory space [2][5]. Financial Highlights - Fourth quarter distribution revenues were $1.3 million, representing an 87% decrease year over year, primarily due to the expiration of the distribution agreement for Dexlansoprazole [5][6]. - Annual distribution revenues totaled $23.6 million, marking a 22% increase year over year, with Dexlansoprazole accounting for 93% of these revenues [5][6]. - The company reported a fourth quarter net loss of $0.4 million, or $0.003 per share, compared to a net income of $0.75 million, or $0.003 earnings per share in the same quarter last year [5][6]. - For the fiscal year, the net loss was $6 million, or $0.041 per share, compared to a net loss of $1.83 million, or $0.012 per share in the previous year, largely due to a one-time goodwill impairment loss of $4.6 million [5][6]. - As of July 31, 2025, the company had $7 million in cash and was debt-free after repaying its long-term debt of $2.2 million during the fiscal year [5][6]. Business Highlights - Devonian completed preclinical studies to explore new applications of Thykamine™ for additional inflammatory diseases, including MASH and fibrosis [6]. - The company is focusing on a phase 2/3 study of Thykamine™ for pediatric mild-to-moderate atopic dermatitis [6]. - Devonian secured additional patent protection related to the mechanisms of action and other therapeutic applications of Thykamine™ [6]. - Pierre Labbé was appointed as a new board member, bringing extensive financial experience to the board [8][9]. About Thykamine™ - Thykamine™, developed from Devonian's SUPREX™ platform, is aimed at treating health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [13][14]. - The product has demonstrated anti-inflammatory, anti-oxidative, and immunomodulatory properties in various studies [13]. Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune inflammatory conditions, leveraging over 15 years of research [14][15]. - The company operates a state-of-the-art extraction facility in Québec and is publicly traded on the TSX Venture Exchange and OTCQB Venture Market [16].